"I've been absolutely blown away by the microRNA field and the way it's blossomed," University of Massachusetts Medical School researcher and Nobel laureate Craig Mello said. "There is just one story after another [showing that] microRNAs … are very critical to many aspects of either disease or development."
According to Nobel laureate Craig Mello, RNAi for research applications "really is very reliable and it works very well. I think where it was over-hyped is this notion that you can just give a patient RNA and expect them to get better."
Miragen Therapeutics, which holds the rights to the discovery, is interested in seeing the work advance. But a company official said that development of a miRNA-targeting drug for ALS would likely only occur in earnest with a partner.